- Claire M. Gelfman has been appointed as the new Chief Scientific Officer of Foundation Fighting Blindness. She will be overlooking the organization’s scientific strategy with a focus on research initiatives to accelerate new therapies for inherited retinal diseases, as well as early translational and preclinical research programs.
- Quantel Medical has launched a new website to share information on dry eye disease (DED). mydryeyedisease.com will give patients a better understanding of the disease, symptoms, and causes, and help them choose the best treatments. With monthly updates and seasonal topics, the website aims to be a practical tool for ophthalmologists to share with their DED patients.
- Santen has announced a global cooperation with Massachusetts Eye and Ear in Boston and Ulster University in Northern Ireland, with the aim of researching, identifying, and developing new glaucoma treatments. Research will focus on preventing and reversing optic nerve damage by exploring innovative therapeutic options for the visual nervous system.
- Oertli has introduced the latest generation of its OS 4 surgical platform for cataract, glaucoma, and retinal surgery. The new platform, with a fully automated user protection filter and a three-pump fluidics system, boasts more speed, precision, and safety. Visualization is improved with the use of two Power LED light sources, which provide 45 percent more light output.
- OPHTEC has introduced its new lens: the Precizon Toric and Precizon Presbyopic IOL. The IOL features a Transitional Conic Toric optic, designed for misalignment tolerance, and a Continuous Transitional Focus, providing a smooth near-to-far transition and a constant defocus between two sharp focal points, as well as a low rate of photic phenomena.
Having edited several technical publications over the last decade, I crossed paths with quite a few of Texere's current team members, and I only ever heard them sing the company's praises. When an opportunity arose to join Texere, I jumped at the chance! With a background in literature, I love the company's ethos of producing genuinely engaging content, and the fact that it is so well received by our readers makes it even more rewarding.
